Last reviewed · How we verify
ABO1105
ABO1105 is a small molecule that targets the PI3K/AKT/mTOR pathway.
ABO1105 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | ABO1105 |
|---|---|
| Sponsor | Suzhou Abogen Biosciences Co., Ltd. |
| Drug class | PI3K/AKT/mTOR pathway inhibitor |
| Target | PI3K/AKT/mTOR pathway |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ABO1105 works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell growth and proliferation. This inhibition can lead to anti-tumor effects. ABO1105 has shown promise in preclinical studies as a potential treatment for various cancers.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above (PHASE1)
- Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABO1105 CI brief — competitive landscape report
- ABO1105 updates RSS · CI watch RSS
- Suzhou Abogen Biosciences Co., Ltd. portfolio CI